Liver Fibrosis - Pipeline Review, H2 2017

Date: September 19, 2017
Pages: 216
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L1EE17B4E07EN
Leaflet:

Download PDF Leaflet

Liver Fibrosis - Pipeline Review, H2 2017
Liver Fibrosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis - Pipeline Review, H2 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape.

Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 7, 3, 1, 1, 51 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Fibrosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Fibrosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Fibrosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Fibrosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Fibrosis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Fibrosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Fibrosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Liver Fibrosis - Overview
Liver Fibrosis - Therapeutics Development
Liver Fibrosis - Therapeutics Assessment
Liver Fibrosis - Companies Involved in Therapeutics Development
Liver Fibrosis - Drug Profiles
Liver Fibrosis - Dormant Projects
Liver Fibrosis - Discontinued Products
Liver Fibrosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Liver Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Liver Fibrosis - Pipeline by Allergan Plc, H2 2017
Liver Fibrosis - Pipeline by Angion Biomedica Corp, H2 2017
Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017
Liver Fibrosis - Pipeline by BioLineRx Ltd, H2 2017
Liver Fibrosis - Pipeline by Bioneer Corp, H2 2017
Liver Fibrosis - Pipeline by BiOrion Technologies BV, H2 2017
Liver Fibrosis - Pipeline by Bird Rock Bio Inc, H2 2017
Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Liver Fibrosis - Pipeline by Cellmid Ltd, H2 2017
Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
Liver Fibrosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals Inc, H2 2017
Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2017
Liver Fibrosis - Pipeline by Dynavax Technologies Corp, H2 2017
Liver Fibrosis - Pipeline by Evotec AG, H2 2017
Liver Fibrosis - Pipeline by FibroGen Inc, H2 2017
Liver Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017
Liver Fibrosis - Pipeline by Galmed Pharmaceuticals Ltd, H2 2017
Liver Fibrosis - Pipeline by Genfit SA, H2 2017
Liver Fibrosis - Pipeline by GenKyoTex SA, H2 2017
Liver Fibrosis - Pipeline by GNI Group Ltd, H2 2017
Liver Fibrosis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Liver Fibrosis - Pipeline by Immuron Ltd, H2 2017
Liver Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017
Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017
Liver Fibrosis - Pipeline by KineMed Inc, H2 2017
Liver Fibrosis - Pipeline by Mission Therapeutics Ltd, H2 2017
Liver Fibrosis - Pipeline by Pfizer Inc, H2 2017
Liver Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017
Liver Fibrosis - Pipeline by Promedior Inc, H2 2017
Liver Fibrosis - Pipeline by Promethera Biosciences SA, H2 2017
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017
Liver Fibrosis - Pipeline by Ribomic Inc, H2 2017
Liver Fibrosis - Pipeline by Samumed LLC, H2 2017
Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2017
Liver Fibrosis - Pipeline by Sirnaomics Inc, H2 2017
Liver Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2017
Liver Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd, H2 2017
Liver Fibrosis - Pipeline by Virobay Inc, H2 2017
Liver Fibrosis - Dormant Projects, H2 2017
Liver Fibrosis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Liver Fibrosis - Dormant Projects, H2 2017 (Contd.2), H2 2017
Liver Fibrosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Liver Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Allergan Plc
Angion Biomedica Corp
Beijing Kawin Technology Share-Holding Co Ltd
BioLineRx Ltd
Bioneer Corp
BiOrion Technologies BV
Bird Rock Bio Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ContraVir Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Dicerna Pharmaceuticals Inc
Dr. Falk Pharma GmbH
Dynavax Technologies Corp
Evotec AG
FibroGen Inc
Galectin Therapeutics Inc
Galmed Pharmaceuticals Ltd
Genfit SA
GenKyoTex SA
GNI Group Ltd
HanAll Biopharma Co Ltd
Immuron Ltd
Intercept Pharmaceuticals Inc
Isarna Therapeutics GmbH
KineMed Inc
Mission Therapeutics Ltd
Pfizer Inc
Pharmaxis Ltd
Promedior Inc
Promethera Biosciences SA
ProMetic Life Sciences Inc
Ribomic Inc
Samumed LLC
Silence Therapeutics Plc
Sirnaomics Inc
TaiwanJ Pharmaceuticals Co Ltd
TCM Biotech International Corp
TRACON Pharmaceuticals Inc
Vascular Biogenics Ltd
Virobay Inc
Skip to top


Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 377 pages
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 278 pages
Cystic Fibrosis - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 387 pages

Ask Your Question

Liver Fibrosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: